Keeping Your Eye on the Outcome – Immune Targets in PsA and SpA
As the number of new and emerging treatment options for patients with PsA continues to expand, dermatology and rheumatology healthcare providers are challenged with keeping pace with the continually escalating amount of clinical trial data and treatment implications of already approved and emerging PsA agents. This activity will provide an overview of not only the most recent safety and efficacy data but also the potential roles of new and emerging therapies.
The goal of this activity is to provide dermatology and rheumatology clinicians with timely, applicable, clinical trial information and expert recommendations to improve their understanding and care of patients with PsA with agents recently approved or under investigation.
This activity has been designed for members of dermatology and rheumatology healthcare provider teams in practices that care for patients who are at-risk for psoriatic arthritis (PsA). No prerequisites required.
Upon completion of this activity, participants will be better able to:
- REVIEW the safety and efficacy data of new and emerging agents for PsA.
- OUTLINE the potential roles of investigational PsA therapies.
M. Elaine Husni, MD, MPH (Chair)
Christopher T. Ritchlin, MD, MPH
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
M. Elaine Husni, MD, MPH (Chair)
Consultant/Advisor: AbbVie Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, UCB Inc.
Royalties/Patents: PASE Questionnaire
|Christopher T. Ritchlin, MD, MPH|
Consultant/Advisor: AbbVie Inc, Amgen Inc, Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals Inc, sanofi-aventis US LLC, Sun Pharmaceutical Industries Ltd, UCB Inc.Research Grant: AbbVie Inc, Amgen Inc, and UCB Inc.
Non-faculty: Daniel Guinee; Nicolle Rochino, PharmD; Sandy Breslow; Leah Johnson; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Pfizer Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Pfizer Inc do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.75 AMA PRA Category 1 Credit(s)™
- 0.75 Non-physician